https://flcube.com/aptar-pharma-secures-nmpa-approval-for-airless-drug-delivery-system-in-chin/2024-10-13T18:56:09+08:00https://flcube.com/strata-skin-sciences-renews-exclusive-distribution-deals-in-china-and-japan/2024-10-13T18:56:06+08:00https://flcube.com/chinas-cde-issues-guidelines-for-semaglutide-biosimilar-clinical-trials-with-weight-management-focus/2024-10-13T18:55:15+08:00https://flcube.com/johnson-johnson-acquires-shockwave-medical-in-a-landmark-deal-to-expand-cardiovascular-portfolio/2024-10-13T18:55:10+08:00https://flcube.com/merck-collaborates-with-caris-life-sciences-to-develop-first-in-class-antibody-drug-conjugates/2024-10-13T18:55:06+08:00https://flcube.com/adicon-launches-guardantomni-test-to-advance-tumor-therapy-development-in-china/2024-10-13T18:55:01+08:00https://flcube.com/luye-pharmas-subsidiary-boan-biotech-completes-phase-iii-trial-for-eylea-biosimilar-ba9101/2024-10-13T18:54:57+08:00https://flcube.com/abbisko-therapeutics-achieves-milestone-in-global-phase-iii-trial-for-pimicotinib-in-tendon-sheath-giant-cell-tumor/2024-10-13T18:54:53+08:00https://flcube.com/medicxi-led-investment-boosts-d3-bios-development-of-best-in-class-oncology-therapies/2024-10-13T18:54:43+08:00https://flcube.com/cstone-pharmaceuticals-submits-new-drug-application-for-gavreto-in-china-eyes-local-manufacturing/2024-10-13T18:54:39+08:00https://flcube.com/transcenta-holdings-ltd-collaborates-with-agilent-technologies-on-companion-diagnostic-for-osemitamab/2024-10-13T18:54:35+08:00https://flcube.com/beijing-aosaikang-pharmaceuticals-achieves-clinical-milestone-for-c-met-inhibitor-askc202/2024-10-13T18:54:30+08:00https://flcube.com/clover-bios-scb-1019-vaccine-candidate-shows-promising-results-in-phase-i-trial/2024-10-13T18:54:19+08:00https://flcube.com/gsks-viiv-healthcare-expands-dovato-indication-to-include-adolescents-with-hiv-1-infection/2024-10-13T18:54:10+08:00https://flcube.com/shanghai-health-commission-implements-strict-guidelines-to-curb-medical-sector-misconduct/2024-10-13T18:54:06+08:00https://flcube.com/shanghais-9th-peoples-hospital-launches-groundbreaking-gene-therapy-trial-for-congenital-deafness/2024-10-13T18:54:01+08:00https://flcube.com/gan-lee-pharmaceuticals-commences-clinical-trial-for-innovative-glp-1-agonist-gzr18/2024-10-13T18:53:51+08:00https://flcube.com/alphamab-oncologys-jskn003-demonstrates-promising-results-in-phase-i-her2-targeted-solid-tumor-study/2024-10-13T18:53:48+08:00https://flcube.com/siemens-healthineers-and-siemens-china-partner-with-fudan-hospital-logistic-service-on-green-imaging-centers/2024-10-13T18:52:19+08:00https://flcube.com/shanghai-henlius-reports-phase-iii-success-for-hlx14-in-osteoporosis-treatment/2024-10-13T18:52:14+08:00https://flcube.com/ipsen-secures-nmpa-approval-for-somatuline-in-advanced-neuroendocrine-tumors/2024-10-13T18:52:09+08:00https://flcube.com/iaso-biotherapeutics-gains-fda-nod-for-fucaso-car-t-study-in-myasthenia-gravis/2024-10-13T18:52:05+08:00https://flcube.com/ascletis-pharma-halts-asc42-phase-ii-study-in-primary-biliary-cholangitis/2024-10-13T18:52:01+08:00https://flcube.com/hinova-pharmaceuticals-receives-nmpa-greenlight-for-hp501-clinical-trial-in-gout-patients/2024-10-13T18:51:53+08:00https://flcube.com/huadong-medicine-gets-nmpa-approval-for-clinical-trial-of-fr%ce%b1-targeting-adc-elahere/2024-10-13T18:51:48+08:00https://flcube.com/zhejiang-dian-diagnostics-partners-with-hangzhou-medical-college-to-establish-education-base/2024-10-13T18:51:38+08:00https://flcube.com/sichuan-kelun-biotech-presents-positive-results-for-sacituzumab-tirumotecan-at-aacr-2024/2024-10-13T18:51:32+08:00https://flcube.com/sino-biopharmaceutical-partners-with-boehringer-ingelheim-to-bring-innovative-cancer-therapies-to-china/2024-10-13T18:51:29+08:00https://flcube.com/dizal-pharmaceuticals-sunvozertinib-earns-fda-breakthrough-therapy-designation-for-nsclc/2024-10-13T18:51:23+08:00https://flcube.com/sanofi-announces-sweeping-restructuring-and-layoffs-in-pipeline-reprioritization-effort/2024-10-13T18:51:19+08:00https://flcube.com/astrazeneca-and-daiichi-sankyos-enhertu-secures-fda-approval-for-her2-positive-solid-tumors/2024-10-13T18:51:10+08:00https://flcube.com/beijing-unveils-comprehensive-measures-to-boost-innovative-medicine-development/2024-10-13T18:51:01+08:00https://flcube.com/novartiss-leqvio-showcases-real-world-efficacy-in-managing-cholesterol-in-ascvd-patients/2024-10-13T18:50:52+08:00https://flcube.com/astrazenecas-imfinzi-achieves-positive-results-in-late-stage-trial-for-small-cell-lung-cancer/2024-10-13T18:50:48+08:00https://flcube.com/junshi-biosciences-files-for-approval-of-ongericimab-targeting-key-cholesterol-disorders/2024-10-13T18:49:51+08:00https://flcube.com/sino-medical-secures-approval-for-innovative-drug-coated-stent-system-targeting-intracranial-stenosis/2024-10-13T18:49:45+08:00https://flcube.com/hepalink-secures-tfda-approval-for-enoxaparin-sodium-injection-expanding-thrombosis-treatment-options-in-thailand/2024-10-13T18:49:41+08:00https://flcube.com/remegen-secures-fast-track-fda-designation-for-telitacicept-in-sjogrens-syndrome-treatment/2024-10-13T18:49:37+08:00https://flcube.com/jiuyuan-genes-semaglutide-biosimilar-market-filing-accepted-for-review-in-china/2024-10-13T18:49:32+08:00https://flcube.com/sichuan-biokin-secures-nmpa-approval-for-phase-ii-study-of-bl-m07d1-in-advanced-solid-tumors/2024-10-13T18:49:23+08:00https://flcube.com/astrazeneca-and-daiichi-sankyo-file-for-fda-approval-of-datopotamab-deruxtecan-in-breast-cancer/2024-10-13T18:49:19+08:00https://flcube.com/remegen-plans-rmb-2-55-billion-private-placement-to-fund-innovative-drug-development/2024-10-13T18:49:15+08:00https://flcube.com/gilead-extends-collaboration-with-nurix-therapeutics-for-targeted-protein-degradation-by-two-years/2024-10-13T18:49:06+08:00https://flcube.com/european-commission-approves-reblozyl-for-first-line-treatment-of-mds-related-anemia/2024-10-13T18:49:01+08:00https://flcube.com/boehringer-ingelheim-to-shut-down-consanas-rehabilitation-unit-in-china-amid-disappointing-performance/2024-10-13T18:48:58+08:00https://flcube.com/genmab-acquires-profound-bio-for-1-8-billion-targeting-expanding-adc-pipeline/2024-10-13T18:48:53+08:00https://flcube.com/legend-biotechs-carvykti-secures-fda-approval-for-expanded-use-in-multiple-myeloma/2024-10-13T18:48:49+08:00https://flcube.com/eisai-forges-strategic-partnership-with-china-resource-medicine-and-china-resources-sanjiu-for-pharmaceutical-collaboration/2024-10-13T18:48:43+08:00https://flcube.com/walvax-biotechnologys-covid-19-variant-vaccine-rq3033-shows-positive-phase-iii-results/2024-10-13T18:48:39+08:00https://flcube.com/bio-thera-solutions-expands-reach-with-new-licensing-deal-for-biosimilar-bat2306/2024-10-13T18:46:17+08:00https://flcube.com/evotec-to-cut-400-jobs-amid-rd-slowdown-and-corporate-restructuring/2024-10-13T18:46:16+08:00https://flcube.com/carsgen-completes-patient-enrollment-for-phase-ii-trial-of-ct041-in-advanced-gastric-cancer/2024-10-13T18:46:00+08:00https://flcube.com/ant-group-eyes-acquisition-of-leading-internet-healthcare-platform-haodf-com/2024-10-13T18:45:54+08:00https://flcube.com/yixintang-partners-with-huawei-cloud-to-drive-digital-transformation-in-pharma-retail/2024-10-13T18:45:09+08:00https://flcube.com/sichuan-biokin-launches-phase-iii-trial-for-bispecific-adc-bl-b01d1-in-lung-cancer/2024-10-13T18:45:05+08:00https://flcube.com/robotrak-secures-nmpa-license-for-chinas-first-smart-ophthalmic-navigation-laser/2024-10-13T18:45:01+08:00https://flcube.com/remegen-reports-75-6-revenue-surge-in-h1-2024-driven-by-key-product-sales/2024-10-13T18:44:56+08:00https://flcube.com/astrazenecas-imfinzi-gains-fda-approval-for-neoadjuvant-use-in-early-stage-lung-cancer/2024-10-13T18:44:52+08:00https://flcube.com/beijing-proposes-new-regulations-to-enhance-pharmaceutical-retail-standards-and-services/2024-10-13T18:44:46+08:00https://flcube.com/lepu-medical-secures-approval-for-recatchor-catheter-enhancing-cardiovascular-procedures/2024-10-13T18:44:43+08:00https://flcube.com/multitude-therapeutics-and-adcendo-aps-partner-on-anti-tf-adc-targeting-global-cancer-treatment/2024-10-13T18:44:38+08:00https://flcube.com/genmabs-tepkinly-epkinly-receives-ec-nod-for-relapsed-lymphoma-treatments/2024-10-13T18:44:33+08:00https://flcube.com/astrazenecas-fasenra-secures-nmpa-approval-for-severe-eosinophilic-asthma-maintenance-therapy/2024-10-13T18:44:28+08:00https://flcube.com/genesis-medtechs-j-valve-system-transfers-to-edwards-lifesciences-marking-a-new-era-in-aortic-valve-treatment/2024-10-13T18:44:17+08:00https://flcube.com/chinas-nmpa-grants-medical-device-license-to-daan-genes-monkeypox-detection-kit/2024-10-13T18:44:11+08:00https://flcube.com/biontechs-bnt326-yl202-clears-fda-hurdle-advancing-in-clinical-trials-for-solid-tumor-treatment/2024-10-13T18:44:02+08:00https://flcube.com/astellas-pharmas-padcev-receives-nmpa-approval-for-urothelial-cancer-treatment/2024-10-13T18:43:56+08:00https://flcube.com/nhsa-flags-concerns-over-pricing-of-microports-castor-aortic-stent-graft-system/2024-10-13T18:43:54+08:00https://flcube.com/yipinhong-pharmacys-ar882-earns-fda-fast-track-status-for-gout-treatment/2024-10-13T18:43:42+08:00https://flcube.com/hasten-biopharmaceutical-gains-nmpa-nod-for-somatostatin-marketing-rights-in-china/2024-10-13T18:43:37+08:00https://flcube.com/genmab-ceo-signals-potential-for-china-partnership-as-biontech-exits-acasunlimab-collaboration/2024-10-13T18:42:38+08:00https://flcube.com/cgps-2024-interim-report-shows-robust-growth-in-revenues-and-profits-highlighting-rd-focus/2024-10-13T18:42:24+08:00https://flcube.com/microport-medtechs-reeamber-catheter-wins-nmpa-nod-for-peripheral-artery-treatments/2024-10-13T18:42:18+08:00https://flcube.com/chinas-national-drug-alliance-procurement-office-imposes-sanctions-on-six-firms-over-collusion-in-bromhexine-bidding/2024-10-13T18:42:13+08:00https://flcube.com/johnson-johnson-to-acquire-israels-v-wave-ltd-in-a-deal-valued-up-to-1-7-billion/2024-10-13T18:42:09+08:00https://flcube.com/astrazenecas-strensiq-gains-approval-for-rare-disease-therapy-in-guangdong-under-hong-kong-macau-drug-and-device-access/2024-10-13T18:42:02+08:00https://flcube.com/cspc-pharmaceutical-group-reports-modest-gains-in-h1-2024-with-patent-medicines-driving-revenue/2024-10-13T18:41:53+08:00https://flcube.com/johnson-johnsons-rybrevant-lazclude-combo-approved-by-fda-for-first-line-nsclc-treatment/2024-10-13T18:41:48+08:00https://flcube.com/finlands-bone-index-partners-with-lynx-financial-for-apac-and-north-american-market-expansion/2024-10-13T18:41:36+08:00https://flcube.com/wuxi-xdc-accelerates-bioconjugate-drug-development-with-67-6-yoy-revenue-increase-in-h1-2024/2024-10-13T18:41:32+08:00https://flcube.com/shanghai-henlius-biotech-secures-exclusive-rights-to-convalife-pharmaceuticals-generic-neratinib-in-china/2024-10-13T18:41:27+08:00https://flcube.com/jiangsu-hansoh-pharmaceutical-and-gsk-win-fda-breakthrough-therapy-designation-for-b7-h3-targeted-adc-in-small-cell-lung-cancer/2024-10-13T18:41:21+08:00https://flcube.com/us-congress-seeks-fda-action-on-china-military-hospital-trials-and-biopharma-security/2024-10-13T18:41:16+08:00https://flcube.com/chinas-vbp-office-exposes-collusion-among-six-firms-in-bromhexine-bidding-process/2024-10-13T18:41:10+08:00https://flcube.com/johnson-johnson-to-acquire-israeli-cardiovascular-device-maker-v-wave-for-upfront-usd-600-million/2024-10-13T18:41:05+08:00https://flcube.com/astrazenecas-strensiq-approved-for-rare-disease-therapy-under-greater-bay-areas-drug-access-policy/2024-10-13T18:40:59+08:00https://flcube.com/cspc-pharmaceutical-group-reports-moderate-h1-2024-revenue-growth-with-patent-medicines-driving-the-increase/2024-10-13T18:40:51+08:00https://flcube.com/jjs-rybrevant-lazclude-combo-approved-by-fda-challenging-astrazenecas-tagrisso-in-nsclc-treatment/2024-10-13T18:40:45+08:00https://flcube.com/bone-index-secures-financing-to-expand-manufacturing-and-promote-diagnostic-technology-globally/2024-10-13T18:39:29+08:00https://flcube.com/wuxi-xdc-reports-67-6-yoy-revenue-growth-and-expands-manufacturing-with-singapore-plant/2024-10-13T18:39:17+08:00https://flcube.com/henlius-biotech-secures-exclusive-rights-to-commercialize-convalifes-generic-neratinib-in-china-and-abroad/2024-10-13T18:39:12+08:00https://flcube.com/jiangsu-hansoh-and-gsk-receive-fda-breakthrough-designation-for-b7-h3-targeted-adc-in-small-cell-lung-cancer/2024-10-13T18:39:08+08:00https://flcube.com/us-congressmen-call-for-fda-investigation-into-clinical-trials-at-chinas-military-hospitals/2024-10-13T18:38:58+08:00https://flcube.com/rd-investments-and-operating-cash-flows-highlight-resilience-in-simcere-pharmas-h1-2024-financial-report/2024-10-13T18:38:51+08:00https://flcube.com/hangzhou-biosunpharmas-ob756-new-drug-application-accepted-for-myelofibrosis-treatment-by-chinas-nmpa/2024-10-13T18:38:37+08:00https://flcube.com/akeso-biopharmas-ivonescimab-earns-category-1-recommendation-in-chinas-2024-lung-cancer-clinical-guideline/2024-10-13T18:38:32+08:00https://flcube.com/synthasia-and-shanghai-general-hospital-partner-to-advance-diabetic-retinopathy-research/2024-10-13T18:38:17+08:00https://flcube.com/changchun-genescience-pharmaceutical-expands-reach-with-huchuang-union-partnership/2024-10-13T18:38:13+08:00https://flcube.com/daiichi-sankyo-launches-tarlige-for-diabetes-peripheral-neuropathic-pain-in-china/2024-10-13T18:38:07+08:00https://flcube.com/sisram-medical-reports-2024-interim-revenues-with-growth-in-key-regions-and-new-product-launches/2024-10-13T18:38:04+08:00https://flcube.com/qilu-pharmaceuticals-biosimilar-ranibizumab-receives-nmpa-approval-marking-a-first-in-china/2024-10-13T18:37:54+08:00https://flcube.com/china-commits-to-optimizing-market-access-for-emerging-sectors-and-global-scientific-collaboration/2024-10-13T18:37:49+08:00https://flcube.com/chinas-nhc-and-nhsa-intensify-efforts-to-stabilize-drug-supply-and-prices-amid-shortages/2024-10-13T18:37:46+08:00https://flcube.com/innovent-biologics-fulzerasib-receives-nmpa-approval-for-advanced-nsclc-treatment-in-china/2024-10-13T18:37:38+08:00https://flcube.com/wuxi-biologics-reports-flat-revenues-with-growth-in-non-covid-19-projects-in-2024h1-financial-report/2024-10-13T18:37:34+08:00https://flcube.com/gsc-to-distribute-hecins-innovative-pcr-and-rt-pcr-solutions-in-middle-eastern-markets/2024-10-13T18:37:29+08:00https://flcube.com/ck-life-sciences-halneuron-receives-fda-fast-track-designation-for-chemotherapy-induced-neuropathic-pain/2024-10-13T18:36:31+08:00https://flcube.com/astellas-pharma-employee-in-china-formally-indicted-on-espionage-suspicion/2024-10-13T18:36:26+08:00https://flcube.com/everest-medicines-launches-trial-for-personalized-mrna-cancer-vaccine-evm16-in-solid-tumors/2024-10-13T18:36:15+08:00https://flcube.com/3sbio-inc-reports-16-yoy-revenue-growth-in-2024-interim-financial-report-highlighting-biomedicine-segment-strength/2024-10-13T18:36:03+08:00https://flcube.com/ascentage-pharmas-2024-interim-results-highlight-477-yoy-revenue-growth-and-first-ever-profitability/2024-10-13T18:35:58+08:00https://flcube.com/uk-mhra-approves-eisai-and-biogens-alzheimers-drug-leqembi-despite-nice-reimbursement-rejection/2024-10-13T18:35:54+08:00https://flcube.com/novartis-and-versant-ventures-launch-borealis-biosciences-with-a-focus-on-rna-medicines-for-kidney-diseases/2024-10-13T18:35:48+08:00https://flcube.com/ocumension-therapeutics-to-repurchase-shares-demonstrating-confidence-and-commitment-to-investor-rights/2024-10-13T18:35:42+08:00https://flcube.com/allgens-medical-technologys-bongold-receives-marketing-approval-from-malaysias-mda/2024-10-13T18:35:37+08:00https://flcube.com/hunan-warrant-pharmaceuticals-zg-002-receives-nmpa-approval-for-clinical-trials-in-plaque-psoriasis/2024-10-13T18:35:32+08:00https://flcube.com/phase-i-success-for-shandong-xinhuas-oab-14-advancing-to-phase-iia-in-alzheimers-therapy/2024-10-13T18:35:21+08:00https://flcube.com/gene-cradle-initiates-first-regulatory-gene-therapy-study-in-china-for-late-onset-pompe-disease/2024-10-13T18:35:14+08:00https://flcube.com/immuneonco-receives-usd-10-million-upfront-payment-from-instil-bio-subsidiary-for-licensing-deal/2024-10-13T18:35:09+08:00https://flcube.com/mabwell-bioscience-receives-approval-for-phase-iii-trial-of-9mw2821-in-cervical-cancer-from-chinas-cde/2024-10-13T18:35:04+08:00https://flcube.com/jiangsu-simcere-pharmaceutical-gets-nmpa-green-light-for-sim0508-clinical-trial-in-advanced-solid-tumors/2024-10-13T18:34:59+08:00https://flcube.com/henlius-biotechs-biosimilar-herceptin-approved-by-health-canada-for-breast-and-gastric-cancer-treatments/2024-10-13T18:34:53+08:00https://flcube.com/china-to-enhance-basic-medical-insurance-coverage-for-residents-in-2024-with-increased-subsidies-and-personal-payments/2024-10-13T18:34:49+08:00https://flcube.com/takeda-prepares-to-file-dengue-fever-vaccine-for-us-approval-expanding-global-regulatory-reach/2024-10-13T18:33:50+08:00https://flcube.com/shouyao-holdings-receives-clinical-trial-approval-for-sy-7166-in-treating-multiple-myeloma/2024-10-13T18:33:44+08:00https://flcube.com/national-healthcare-security-administration-reports-pricing-revisions-on-aortic-stent-grafts-by-major-manufacturers/2024-10-13T18:33:40+08:00https://flcube.com/guangzhou-based-bio-thera-solutions-expands-market-presence-with-biosimilars-and-innovative-drug-approvals/2024-10-13T18:33:36+08:00https://flcube.com/us-fda-approves-updated-covid-19-mrna-vaccines-from-pfizer-biontech-and-moderna-ahead-of-winter/2024-10-13T18:33:30+08:00https://flcube.com/suzhou-based-medical-device-innovator-ensurge-secures-rmb-100-million-in-latest-financing-round/2024-10-13T18:33:27+08:00https://flcube.com/cstone-pharmaceuticals-reports-2024-interim-results-with-strategic-collaborations-and-regulatory-milestones/2024-10-13T18:33:22+08:00https://flcube.com/mabwell-bioscience-initiates-phase-iii-trial-for-9mw2821-combo-in-urothelial-carcinoma-following-nmpa-clearance/2024-10-13T18:33:16+08:00https://flcube.com/chinese-nmpa-grants-license-to-microport-endovascular-medtechs-venous-stent-for-treating-vascular-conditions/2024-10-13T18:32:57+08:00https://flcube.com/chinas-cde-approves-multitude-therapeutics-amt-676-for-clinical-study-in-solid-tumors/2024-10-13T18:32:53+08:00https://flcube.com/fosun-pharmas-privatization-of-henlius-includes-cash-and-share-offers-aims-for-full-equity-control/2024-10-13T18:32:48+08:00https://flcube.com/innovent-biologics-president-liu-yongjun-resigns-ceo-de-chao-micheal-yu-takes-rd-reins/2024-10-13T18:32:42+08:00https://flcube.com/shanghai-pharmaceuticals-posts-5-14-yoy-revenue-growth-in-2024h1-with-focus-on-cell-therapies/2024-10-13T18:32:34+08:00https://flcube.com/microport-endovascular-medtech-reports-26-63-yoy-revenue-growth-and-strong-rd-investment-in-2024h1/2024-10-13T18:32:30+08:00https://flcube.com/diversifying-hpv-protection-beijing-wantais-vaccine-filing-competes-with-gardasil-9-in-china/2024-10-13T18:32:19+08:00https://flcube.com/shanghai-henlius-biotech-reports-9-8-yoy-revenue-growth-and-continued-profitability-in-2024h1-financial-report/2024-10-13T18:31:59+08:00https://flcube.com/chinas-guilin-sanjin-pharmaceutical-advances-bc011-with-nmpa-approval-for-phase-i-clinical-trial/2024-10-13T18:31:48+08:00https://flcube.com/shanghai-fudan-zhangjiang-enrolls-first-patient-in-phase-iii-trial-for-trop2-adc-fda018-in-tnbc/2024-10-13T18:05:51+08:00https://flcube.com/shenzhen-salubris-pharmaceuticals-inks-licensing-deal-for-yoltech-therapeutics-yolt-101-gene-editing-therapy/2024-10-13T18:05:46+08:00https://flcube.com/ucb-agrees-to-usd-680-million-divestment-of-china-neurology-and-allergy-business-to-cbc-group-and-mubadala/2024-10-13T18:05:42+08:00https://flcube.com/chinas-work-medical-technology-targets-u-s-market-with-upcoming-ipo/2024-10-13T18:05:34+08:00https://flcube.com/peking-union-medical-college-innovates-with-angle-positioning-device-patent-sale/2024-10-13T18:05:29+08:00https://flcube.com/nhsa-updates-nrdl-review-adds-three-domestic-western-medicines/2024-10-13T18:05:15+08:00https://flcube.com/takedas-entyvio-receives-historic-patent-term-adjustment-in-china-a-first-for-the-country/2024-10-13T18:05:11+08:00https://flcube.com/bio-thera-solutions-bat8006-receives-nmpa-approval-for-clinical-trial-in-recurrent-ovarian-cancer-maintenance-therapy/2024-10-13T18:05:00+08:00https://flcube.com/walvax-biotechnology-reports-2024h1-revenue-dip-amid-intense-vaccine-market-competition/2024-10-13T18:04:55+08:00https://flcube.com/hinova-pharmaceuticals-hp515-receives-nmpa-approval-for-nash-clinical-study/2024-10-13T18:04:51+08:00https://flcube.com/luye-pharmas-subsidiary-boan-bio-reports-2024h1-revenue-growth-and-first-full-year-of-profitability/2024-10-13T18:04:46+08:00https://flcube.com/legend-biotechs-carvykti-receives-nmpa-approval-for-relapsed-refractory-multiple-myeloma-after-multi-center-phase-ii-study/2024-10-13T18:04:35+08:00https://flcube.com/shanghai-fosun-pharmaceutical-reports-5-31-yoy-revenue-growth-and-strong-rd-investment-in-2024h1-report/2024-10-13T18:04:26+08:00https://flcube.com/shanghai-based-anext-commences-clinical-trials-for-exosome-product-anext-fit-cell-in-respiratory-conditions/2024-10-13T18:04:21+08:00https://flcube.com/jw-therapeutics-car-t-therapy-carteyva-secures-nmpa-approval-for-mantle-cell-lymphoma-indication/2024-10-13T18:04:18+08:00https://flcube.com/everest-medicines-reports-158-revenue-growth-in-2024-h1-driven-by-pharmaceutical-sales-and-operational-efficiency/2024-10-13T18:03:17+08:00https://flcube.com/johnson-johnson-chinas-cardiovascular-and-professional-solutions-division-head-kevin-chen-resigns-for-new-opportunities/2024-10-13T18:03:12+08:00https://flcube.com/frontier-biotechnologies-to-sell-70-of-api-unit-to-duo-rui-pharma-for-rmb-10-million/2024-10-13T18:03:08+08:00https://flcube.com/sanofi-halts-flu-vaccine-distribution-in-china-amid-potency-concerns/2024-10-13T18:03:03+08:00https://flcube.com/peijia-medical-secures-exclusive-rights-to-nowyons-yonflow-device-in-greater-china/2024-10-13T18:02:58+08:00https://flcube.com/astrazeneca-to-invest-135-million-in-swedish-biomanufacturing-facility-expansion/2024-10-13T18:02:54+08:00https://flcube.com/online-pharmacy-service-drives-jianke-coms-revenue-growth-in-h1-2024-amid-diverse-business-segments/2024-10-13T18:02:38+08:00https://flcube.com/asieris-pharmaceuticals-reports-explosive-103397-96-yoy-revenue-growth-in-2024h1-financial-report/2024-10-13T18:02:33+08:00https://flcube.com/luye-pharma-groups-2024h1-revenue-and-net-profits-surge-driven-by-oncology-and-cns-therapy-revenues/2024-10-13T18:02:29+08:00https://flcube.com/tigermed-partners-with-beijing-government-to-open-north-headquarters-expanding-collaboration-in-biotech/2024-10-13T18:02:23+08:00https://flcube.com/innovent-biologics-reports-46-3-yoy-revenue-growth-and-expands-portfolio-with-new-approvals-and-ndas/2024-10-13T18:02:19+08:00https://flcube.com/chinas-new-medical-device-regulations-a-comprehensive-framework-for-industry-growth-and-safety/2024-10-13T18:02:14+08:00https://flcube.com/advancing-peripheral-artery-disease-care-boston-scientifics-jetstream-receives-marketing-nod-in-china/2024-10-13T18:02:07+08:00https://flcube.com/leaderna-therapeutics-secures-rmb-100-million-in-funding-to-accelerate-nucleic-acid-drug-development/2024-10-13T18:02:01+08:00https://flcube.com/sino-biopharmaceuticals-anlotinib-penpulimab-combo-meets-milestone-in-phase-iii-hcc-study/2024-10-13T18:01:57+08:00https://flcube.com/jiangsu-simcere-and-andiconbios-anti-influenza-drug-adc189-doses-first-patient-in-phase-iii-study/2024-10-13T18:01:52+08:00https://flcube.com/sackler-owned-mundipharma-fails-to-secure-1-billion-valuation-for-china-unit/2024-10-13T18:01:44+08:00https://flcube.com/pfizer-partners-with-quotient-therapeutics-for-somatic-mutations-research-in-cardiovascular-and-renal-diseases/2024-10-13T18:01:39+08:00https://flcube.com/nmpa-suspends-jeisys-medical-inc-s-ndyag-laser-equipment-over-quality-concerns/2024-10-13T18:00:40+08:00https://flcube.com/astrazeneca-boosts-investment-in-qingdao-aerosol-production-hub-to-750-million/2024-10-13T18:00:35+08:00https://flcube.com/jiyuan-biotechnologys-stem-cell-therapy-for-type-2-diabetes-gains-nmpa-tacit-approval-for-clinical-trials/2024-10-13T18:00:28+08:00https://flcube.com/doma-biopharmaceutical-receives-fda-clearance-for-phase-i-trial-of-egfr-met-targeting-adc-dm005/2024-10-13T18:00:24+08:00https://flcube.com/microport-cardioflow-to-acquire-rmb-380-million-shanghai-assets-for-global-hq-expansion/2024-10-13T18:00:10+08:00https://flcube.com/hutchmed-withdraws-fruquintinibs-new-indication-application-in-china-seeks-alternative-regulatory-path/2024-10-13T17:59:46+08:00https://flcube.com/sino-medical-sciences-secures-hong-kong-approval-for-coronary-balloon-dilation-catheter/2024-10-13T17:59:42+08:00https://flcube.com/chinas-supreme-court-deals-blow-to-sanofis-aubagio-confirms-patent-cancellation/2024-10-13T17:59:36+08:00https://flcube.com/jiangxi-healthcare-security-administration-launches-initiative-to-widen-drug-availability/2024-10-13T17:59:30+08:00https://flcube.com/genequantum-appoints-dr-lingyu-zhu-as-chief-business-strategy-and-development-officer/2024-10-13T17:59:25+08:00https://flcube.com/american-government-funds-bolster-chinese-inventors-patents-according-to-uspto-data/2024-10-13T17:59:20+08:00https://flcube.com/hua-medicines-2024h1-revenues-surge-on-huatangning-sales-path-to-profitability-in-sight/2024-10-13T17:59:12+08:00https://flcube.com/mindray-bio-medical-electronics-reports-11-12-yoy-revenue-growth-in-2024h1/2024-10-13T17:59:06+08:00https://flcube.com/chinas-healthcare-statistics-show-improvements-in-life-expectancy-and-access-to-medical-services/2024-10-13T17:59:03+08:00https://flcube.com/bio-thera-solutions-bat2406-biosimilar-gets-green-light-for-clinical-trials-in-china/2024-10-13T17:56:29+08:00https://flcube.com/allist-pharmaceuticals-acquires-jacobios-g12c-inhibitor-and-shp2-inhibitor-rights-for-greater-china-region/2024-10-13T17:56:18+08:00https://flcube.com/hybio-pharmaceutical-inks-licensing-deal-with-mullan-pharmaceutical-for-liraglutide-biosimilar/2024-10-13T17:56:14+08:00https://flcube.com/accuredit-therapeutics-gene-editing-drug-art001-clears-fda-hurdle-for-us-clinical-trials/2024-10-13T17:56:07+08:00https://flcube.com/novo-nordisk-to-resubmit-wegovy-heart-failure-application-with-updated-clinical-data/2024-10-13T17:55:59+08:00https://flcube.com/zuellig-pharma-partners-with-regeneron-for-libtayo-launch-in-south-korea-and-taiwan/2024-10-13T17:55:54+08:00https://flcube.com/sinocelltechs-anti-angiogenic-biologic-sct520ff-gets-nmpa-green-light-for-neovascular-amd-clinical-study/2024-10-13T17:54:07+08:00https://flcube.com/genequantum-healthcares-gq1005-adc-receives-cde-clearance-for-phase-iii-breast-cancer-trial/2024-10-13T17:53:58+08:00https://flcube.com/jiangsu-simcere-acquires-exclusive-rights-to-targetrxs-tgrx-326-in-licensing-deal/2024-10-13T17:53:49+08:00https://flcube.com/jiangsu-simceres-edaravone-borneol-sublingual-tablet-earns-fda-breakthrough-therapy-designation-for-stroke-treatment/2024-10-13T17:53:44+08:00https://flcube.com/epimabs-emb-06-secures-635-million-licensing-agreement-with-vignette-for-multiple-myeloma-therapy/2024-10-13T17:53:26+08:00https://flcube.com/chinas-13-ministries-unite-to-chart-a-healthier-future-for-rural-communities/2024-10-13T17:53:01+08:00https://flcube.com/jafron-biomedicals-blood-purification-devices-gain-eu-market-approval-under-mdr/2024-10-13T17:52:56+08:00https://flcube.com/innovent-biologics-ibi363-earns-fda-fast-track-designation-for-advanced-melanoma-treatment/2024-10-13T17:51:48+08:00https://flcube.com/cgenetech-secures-rmb-100-million-in-series-c-financing-to-advance-drug-commercialization-and-clinical-pipeline/2024-10-13T17:51:41+08:00https://flcube.com/skyline-therapeutics-gene-therapy-receives-fda-orphan-drug-designation-for-retinitis-pigmentosa-treatment/2024-10-13T17:51:36+08:00https://flcube.com/manufacturing-challenges-for-novo-nordisks-ozempic-impact-diabetes-and-obesity-treatments-in-europe/2024-10-13T17:51:30+08:00https://flcube.com/european-commission-approves-mercks-keytruda-padcev-combo-for-first-line-urothelial-carcinoma-treatment/2024-10-13T17:51:26+08:00https://flcube.com/aspen-pharmacares-2024-fiscal-report-shows-mixed-results-amid-chinas-vbp-impact/2024-10-13T17:51:21+08:00https://flcube.com/e-commerce-and-physical-stores-to-stock-hanmis-otc-drugs-following-shanghai-pharma-deal/2024-10-13T17:51:12+08:00https://flcube.com/sage-group-expands-into-chinas-healthcare-market-with-cenponts-healthcare-partnership/2024-10-13T17:50:56+08:00https://flcube.com/jiangsu-suzhou-launches-843-million-biomedicine-fund-to-boost-pharma-and-medical-device-innovation/2024-10-13T17:50:49+08:00https://flcube.com/novartis-builds-two-radioligand-therapy-facilities-in-u-s-to-expand-cancer-treatment-capabilities/2024-10-13T17:49:54+08:00https://flcube.com/us-allows-science-and-technology-agreement-with-china-to-expire-pointing-to-deepening-rd-competition/2024-10-13T17:49:40+08:00https://flcube.com/roches-columvi-for-relapsed-dlbcl-gets-review-nod-from-chinas-cde-for-new-indication/2024-10-13T17:49:10+08:00https://flcube.com/eli-lilly-partners-with-haya-therapeutics-to-tap-the-dark-genome-for-obesity-treatments/2024-10-13T17:48:58+08:00https://flcube.com/astrazeneca-china-restructures-biopharma-unit-to-boost-chronic-disease-management/2024-10-13T17:48:33+08:00https://flcube.com/novo-nordisk-advances-in-china-with-submission-of-sogroya-for-adult-growth-hormone-deficiency/2024-10-13T17:48:22+08:00https://flcube.com/sansure-biotech-wins-nmpa-nod-for-aldh2-gene-polymorphism-detection-kit/2024-10-13T17:48:09+08:00https://flcube.com/viatris-launches-first-of-its-kind-nasal-spray-dymista-in-china-for-allergic-rhinitis/2024-10-13T17:47:55+08:00https://flcube.com/chinas-hainan-free-trade-port-implements-zero-tax-on-medical-imports-for-designated-entities/2024-10-13T17:47:43+08:00https://flcube.com/venus-medtech-initiates-global-study-with-venus-vitae-tavr-system-implantations/2024-10-13T17:47:22+08:00https://flcube.com/true-healths-advanced-microwave-ablation-system-gains-nmpa-nod-for-liver-tumor-treatment/2024-10-13T17:47:10+08:00https://flcube.com/genesis-medtech-secures-nmpa-approval-for-innovative-surgical-energy-products/2024-10-13T17:46:56+08:00https://flcube.com/jiangsu-kanion-pharmaceutical-gets-nmpa-go-ahead-for-psoriasis-drug-clinical-trial/2024-10-13T17:46:44+08:00https://flcube.com/fujirebios-hbsag-detection-kit-receives-nmpa-approval-enhances-early-diagnosis-capabilities/2024-10-13T17:46:33+08:00https://flcube.com/voyager-therapeutics-secures-licensing-deal-with-novartis-for-gene-therapy-capsid/2024-10-13T17:46:18+08:00https://flcube.com/sinocelltechs-herpes-zoster-vaccine-sctv04c-clears-nmpa-for-clinical-trial/2024-10-13T17:46:07+08:00https://flcube.com/rigel-pharmaceuticals-strikes-deal-with-kissei-for-development-and-commercialization-of-rezlidhia-in-east-asia/2024-10-13T17:45:54+08:00https://flcube.com/euroapi-to-downsize-api-production-citing-asian-competition-and-market-stagnation/2024-10-13T17:45:43+08:00https://flcube.com/eli-lilly-partners-with-genetic-leap-for-rna-targeted-ai-drug-discovery/2024-10-13T17:45:16+08:00https://flcube.com/u-s-house-of-representatives-to-review-the-biosecure-act-amid-legislative-hurdles/2024-10-13T17:44:18+08:00https://flcube.com/astrazeneca-faces-investigation-in-china-over-data-privacy-and-unapproved-drugs/2024-10-13T17:44:05+08:00https://flcube.com/akesos-ivonescimab-shows-promising-results-in-phase-iii-clinical-trial-for-hepatocellular-carcinoma/2024-10-13T17:43:54+08:00https://flcube.com/chinas-cde-releases-86th-batch-of-reference-preparations-for-generic-drug-evaluation/2024-10-13T17:43:41+08:00https://flcube.com/biosecure-act-faces-opposition-from-senior-house-democrat-jim-mcgovern/2024-10-13T17:43:25+08:00https://flcube.com/guangzhou-health-commission-unveils-ten-measures-to-boost-innovative-pharma-and-medical-device-development/2024-10-13T17:43:01+08:00https://flcube.com/connect-biopharma-shifts-focus-to-us-plans-further-reduction-in-china-workforce/2024-10-13T17:42:48+08:00https://flcube.com/china-opens-doors-to-foreign-biotech-and-wholly-owned-hospitals-in-healthcare-sector-expansion/2024-10-13T17:42:37+08:00https://flcube.com/chinas-nhsa-proposes-new-guidelines-to-enhance-oversight-of-medical-insurance-funds/2024-10-13T17:42:06+08:00https://flcube.com/zelgen-biopharmas-zg006-shows-promising-anti-tumor-efficacy-in-phase-i-ii-sclc-study/2024-10-13T17:41:53+08:00https://flcube.com/edwards-lifesciences-sells-icu-business-to-bd-in-4-2-billion-deal-announces-layoffs/2024-10-13T17:41:41+08:00https://flcube.com/chinas-nmpa-proposes-inclusion-of-cochlear-implants-in-volume-based-procurement-plans/2024-10-13T17:41:29+08:00https://flcube.com/chinas-2024-negative-list-eases-restrictions-on-foreign-investment-in-tcm-and-biotechnology/2024-10-13T17:41:16+08:00https://flcube.com/tigermed-partners-with-purpose-africa-to-boost-clinical-research-and-healthcare-cooperation/2024-10-13T17:41:05+08:00https://flcube.com/chinas-cde-issues-draft-guidelines-for-biosimilar-pharmaceutical-similarity-research/2024-10-13T17:40:54+08:00https://flcube.com/innovent-biologics-dupert-demonstrates-positive-results-in-phase-ii-nsclc-trial/2024-10-13T17:40:41+08:00https://flcube.com/nhc-releases-updated-list-of-pediatric-drugs-for-research-and-development-incentives/2024-10-13T17:40:30+08:00https://flcube.com/insilico-medicine-partners-with-inimmune-corporation-to-utilize-ai-for-immunotherapy-innovation/2024-10-13T17:40:17+08:00https://flcube.com/vcanbios-stem-cell-therapy-vum02-gets-nmpa-approval-for-systemic-sclerosis-clinical-trial/2024-10-13T17:40:03+08:00https://flcube.com/candel-therapeutics-acquires-bispecific-antibodies-and-secures-370-million-in-financing-for-autoimmune-drug-development/2024-10-13T17:39:53+08:00https://flcube.com/astrazeneca-and-daiichi-sankyos-dato-dxd-misses-overall-survival-endpoint-but-shows-promise-in-nsclc-subgroup/2024-10-13T17:39:41+08:00https://flcube.com/amoy-diagnostics-aihuijie-lung-cancer-companion-diagnostic-receives-nmpa-approval/2024-10-13T17:39:28+08:00https://flcube.com/jhm-biopharma-secures-over-usd-28-million-in-series-b-financing-to-boost-pipeline-development/2024-10-13T17:39:14+08:00https://flcube.com/beijing-centergate-technologies-and-bestcomm-pharmaceutical-form-strategic-partnership-in-multiple-medical-fields/2024-10-13T17:38:34+08:00https://flcube.com/fosun-pharmaceuticals-daxxify-receives-nmpa-approval-for-aesthetic-use-in-china/2024-10-13T17:38:15+08:00https://flcube.com/us-house-approves-biosecure-act-with-implications-for-chinese-biotech-firms/2024-10-13T17:37:44+08:00https://flcube.com/gsks-nucala-shows-promise-in-phase-iii-copd-trial-matinee-results-positive/2024-10-13T17:37:32+08:00https://flcube.com/terns-pharmaceuticals-oral-glp-1r-agonist-tern-601-shows-promising-weight-loss-results-in-phase-i-trial/2024-10-13T17:37:16+08:00https://flcube.com/medtronic-secures-china-market-approval-for-pulsed-electric-field-atrial-fibrillation-treatment-devices/2024-10-13T17:36:35+08:00https://flcube.com/betta-pharmaceuticals-mcla129-for-advanced-solid-tumors-accepted-for-review-by-chinas-nmpa/2024-10-13T17:36:02+08:00https://flcube.com/innovent-biologics-presents-promising-phase-i-data-for-ibi363-in-advanced-nsclc-at-wclc/2024-10-13T17:35:48+08:00https://flcube.com/nuance-pharma-completes-enrollment-for-phase-iii-copd-trial-of-ohtuvayre-in-china/2024-10-13T17:35:23+08:00https://flcube.com/qilu-pharmaceuticals-iruplinalkib-shows-promising-results-in-phase-ii-study-for-alk-nsclc/2024-10-13T17:34:58+08:00https://flcube.com/itcure-expands-gene-editing-reach-with-collaborations-in-chinas-biotech-sector/2024-10-13T17:34:46+08:00https://flcube.com/carisma-therapeutics-and-moderna-expand-partnership-to-target-autoimmune-diseases-with-car-m-therapies/2024-10-13T17:34:32+08:00https://flcube.com/gilead-sciences-partners-with-ai-firm-genesis-therapeutics-to-develop-novel-small-molecule-therapies/2024-10-13T17:34:21+08:00https://flcube.com/celltrion-inc-enters-cdmo-arena-amid-shifts-in-global-biosecurity-landscape/2024-10-13T17:34:09+08:00https://flcube.com/csa-medical-inc-secures-usd-53-million-in-series-d-financing-to-advance-cryotherapy-treatment/2024-10-13T17:33:59+08:00https://flcube.com/innovent-biologics-mazdutide-outperforms-dulaglutide-in-phase-iii-t2d-study-at-easd-meeting/2024-10-13T17:33:49+08:00https://flcube.com/suzhou-genassist-launches-first-of-its-kind-base-editing-drug-trial-for-duchenne-muscular-dystrophy/2024-10-13T17:33:37+08:00https://flcube.com/china-aims-to-fortify-insurance-industry-by-2035-with-new-state-council-directives/2024-10-13T17:33:23+08:00https://flcube.com/signet-therapeutics-and-jennio-biotech-join-forces-to-advance-tumor-immunotherapy/2024-10-13T17:33:07+08:00https://flcube.com/luye-pharmas-subsidiary-boan-biotech-partners-with-haier-biomedical-for-pharmaceutical-industry-digitalization/2024-10-13T17:32:54+08:00https://flcube.com/oxford-nanopore-sets-sights-on-bgi-in-uk-courts-over-nanopore-sequencing-technology/2024-10-13T17:32:41+08:00https://flcube.com/fda-uncovers-data-management-failures-in-medical-device-labs-assessing-regulatory-impact/2024-10-13T17:32:09+08:00https://flcube.com/sanofis-dupixent-shows-promise-in-phase-iii-trials-for-rare-skin-disease-and-chronic-hives/2024-10-13T17:31:48+08:00https://flcube.com/yestar-healthcares-2024-interim-report-reflects-impact-of-volume-based-procurement-on-revenue/2024-10-13T17:31:37+08:00https://flcube.com/autobio-diagnostics-partners-with-mbl-to-advance-microbial-mass-spectrometry-technology/2024-10-13T17:31:17+08:00https://flcube.com/leadership-shuffle-at-chinas-national-health-commission-liu-jinfeng-steps-in-as-deputy-director/2024-10-13T17:31:05+08:00https://flcube.com/beijings-moleculemind-secures-series-a-funding-to-accelerate-ai-protein-design-innovations/2024-10-13T17:30:51+08:00https://flcube.com/nona-biosciences-and-umoja-biopharma-join-forces-to-develop-in-vivo-car-t-therapies/2024-10-13T17:30:40+08:00https://flcube.com/alibaba-health-forges-strategic-partnerships-with-viatris-and-chinese-pharma-companies-for-digital-health-expansion/2024-10-13T17:29:58+08:00https://flcube.com/south-koreas-mfds-aims-to-slash-drug-approval-times-with-new-innovation-plan/2024-10-13T17:29:47+08:00https://flcube.com/keymed-biosciences-il-4r%ce%b1-mab-stapokibart-receives-nmpa-approval-for-atopic-dermatitis-treatment/2024-10-13T17:29:36+08:00https://flcube.com/johnson-johnson-submits-second-nda-for-nipocalimab-to-treat-generalized-myasthenia-gravis/2024-10-13T17:29:17+08:00https://flcube.com/sino-biological-and-biogeometry-broaden-partnership-to-advance-ai-driven-drug-discovery/2024-10-13T17:28:06+08:00https://flcube.com/moderna-inc-announces-cost-cutting-measures-and-pipeline-realignment/2024-10-13T17:27:53+08:00https://flcube.com/cde-launches-care-plan-to-streamline-rare-disease-drug-development/2024-10-13T17:27:42+08:00https://flcube.com/chinas-nhsa-and-mof-issue-notices-to-enhance-cross-regional-medical-treatment-direct-settlement/2024-10-13T17:27:31+08:00https://flcube.com/china-boosts-public-health-subsidies-and-targets-weight-management-in-2024/2024-10-13T17:27:14+08:00https://flcube.com/mgi-tech-and-sequanta-technologies-launch-advanced-dcs-lab-to-accelerate-omics-research/2024-10-13T17:26:53+08:00https://flcube.com/mgi-tech-and-haihe-laboratory-deepen-collaboration-with-introduction-of-cycloneseq-wt02/2024-10-13T17:26:42+08:00https://flcube.com/hangzhou-based-ophthalmic-device-maker-mdco-secures-rmb-200-million-in-series-b-funding/2024-10-13T17:26:16+08:00https://flcube.com/astrazenecas-fasenra-secures-fda-nod-for-egpa-treatment-strengthening-rare-disease-portfolio/2024-10-13T17:16:21+08:00https://flcube.com/ascentage-pharma-receives-approval-for-two-phase-iii-trials-of-apg-2449-in-nsclc/2024-10-13T17:12:20+08:00https://flcube.com/biogens-china-unit-gets-conditional-nmpa-nod-for-qalsody-tofersen-in-als-treatment/2024-10-13T17:10:33+08:00https://flcube.com/pfizer-halts-development-of-sisunatovir-an-rsv-antiviral-after-phase-ii-iii-trials/2024-10-13T17:10:21+08:00https://flcube.com/eli-lilly-appoints-thomas-j-fuchs-as-first-chief-ai-officer-to-lead-ai-initiatives/2024-10-13T17:09:54+08:00https://flcube.com/mercks-keytruda-meets-primary-endpoint-in-phase-iii-study-for-head-and-neck-cancer/2024-10-13T17:09:32+08:00https://flcube.com/sichuan-biokins-bl-b01d1-earns-breakthrough-therapy-designation-for-esophageal-cancer-from-chinas-cde/2024-10-13T17:09:20+08:00https://flcube.com/hitgen-inc-partners-with-ablink-biotech-to-develop-antibody-oligonucleotide-conjugates/2024-10-13T17:09:01+08:00https://flcube.com/ascletis-pharmas-asc40-earns-fda-breakthrough-therapy-designation-for-fibrotic-mash/2024-10-13T17:08:48+08:00https://flcube.com/innocare-pharma-achieves-positive-phase-ii-results-for-tyk2-inhibitor-icp-488-in-psoriasis-treatment/2024-10-13T17:08:36+08:00https://flcube.com/shanghai-releases-local-guidelines-to-correct-unhealthy-practices-in-pharmaceutical-procurement-and-medical-services/2024-10-13T17:08:25+08:00https://flcube.com/eli-lilly-china-appoints-yan-qiong-as-vice-president-of-diabetes-business-unit/2024-10-13T17:08:14+08:00https://flcube.com/beijing-aosaikang-pharmaceuticals-boosts-stake-in-us-subsidiary-askgene-with-rmb-220-million-investment/2024-10-13T17:08:03+08:00https://flcube.com/ascletis-pharma-faces-us-import-ban-for-nash-drugs-asc41-and-asc43f-in-trade-secrets-dispute/2024-10-13T17:07:54+08:00https://flcube.com/innocare-pharmas-icp-488-shows-promising-results-in-phase-ii-psoriasis-study/2024-10-13T17:07:40+08:00https://flcube.com/nona-biosciences-partners-with-overt-bio-to-develop-next-generation-cell-therapies-for-solid-tumors/2024-10-13T17:06:54+08:00https://flcube.com/sino-medical-sciences-secures-nmpa-nod-for-balloon-guided-catheter-to-aid-vascular-procedures/2024-10-13T17:06:21+08:00https://flcube.com/chinas-nmpa-proposes-rewards-for-internal-whistleblowers-in-drug-and-medical-device-safety-reporting/2024-10-13T17:05:48+08:00https://flcube.com/eli-lilly-co-boosts-suzhou-plant-with-211m-to-meet-diabetes-and-obesity-drug-demand/2024-10-13T17:05:32+08:00https://flcube.com/roches-ventana-cldn18-assay-receives-eu-approval-enhances-targeted-therapy-options-for-gastric-cancer/2024-10-13T17:05:01+08:00https://flcube.com/johnson-johnsons-darzalex-combo-therapy-gets-ema-nod-for-multiple-myeloma-aims-to-set-new-standard/2024-10-13T17:03:57+08:00https://flcube.com/roches-genentech-scores-fda-approval-for-itovebi-in-advanced-breast-cancer-treatment-advancing-personalized-oncology/2024-10-13T17:03:38+08:00https://flcube.com/eli-lilly-expands-collaboration-with-keybioscience-to-develop-obesity-treatments-using-dacra-platform/2024-10-13T17:02:50+08:00https://flcube.com/harbour-biomeds-innovative-antibody-porustobart-shows-promise-in-early-clinical-trials-for-melanoma/2024-10-13T17:02:33+08:00https://flcube.com/doma-biopharmaceutical-receives-green-light-for-clinical-trial-of-novel-adc-dm001-targeting-solid-tumors/2024-10-13T17:02:16+08:00https://flcube.com/coherent-biopharmas-cbp-1008-earns-fda-fast-track-for-platinum-resistant-ovarian-cancer/2024-10-13T17:01:59+08:00https://flcube.com/huadong-medicine-secures-nmpa-approval-for-semaglutide-biosimilar-aims-to-capture-weight-loss-market/2024-10-13T17:01:36+08:00https://flcube.com/hetero-and-gilead-sciences-partner-to-expand-access-to-hiv-treatment-in-low-income-countries/2024-10-13T17:01:16+08:00https://flcube.com/eli-lilly-co-partners-with-insitro-to-leverage-ai-in-metabolic-disease-drug-development/2024-10-13T17:00:38+08:00https://flcube.com/immupeutics-medicine-secures-nmpa-approval-for-personalized-liver-cancer-immunotherapy-ipm001/2024-10-13T17:00:06+08:00https://flcube.com/guangdong-province-aims-for-rmb-one-trillion-in-biopharma-industry-growth-by-2027/2024-10-13T16:59:47+08:00https://flcube.com/samr-proposes-guidelines-to-curb-commercial-bribery-in-pharmaceutical-industry/2024-10-13T16:59:09+08:00https://flcube.com/sanofi-commences-negotiations-with-cdr-for-potential-sale-of-opella-stake/2024-10-13T16:58:49+08:00https://flcube.com/juventas-cell-therapys-car-t-therapy-clears-for-sle-itp-study-in-china/2024-10-13T16:58:25+08:00https://flcube.com/wuxi-apptec-addresses-media-speculation-on-potential-sale-of-wuxi-atu/2024-10-13T16:57:55+08:00https://flcube.com/junshi-biosciences-ongericimab-wins-nmpa-nod-for-hypercholesterolemia-treatment/2024-10-13T16:57:38+08:00https://flcube.com/merck-kgaas-pergoveris-treatment-expands-access-to-advanced-reproductive-care-in-greater-bay-area/2024-10-13T16:57:19+08:00https://flcube.com/johnson-johnsons-klk2-cd3-bispecific-antibody-jnj-78278343-advances-in-prostate-cancer-clinical-trials/2024-10-13T16:56:59+08:00https://flcube.com/kangabios-kgx101-receives-nmpa-approval-for-clinical-trial-in-china/2024-10-13T16:56:41+08:00https://flcube.com/luye-pharmas-subsidiary-gets-nmpa-green-light-for-biosimilar-xgeva/2024-10-12T11:27:03+08:00https://flcube.com/bio-thera-solutions-bevacizumab-biosimilar-avzivi-recommended-for-approval-by-emas-chmp/2024-10-12T11:24:13+08:00https://flcube.com/mabwell-bioscience-partners-with-cristalia-for-biosimilar-denosumab-in-brazil/2024-10-12T11:12:59+08:00https://flcube.com/asieris-pharmaceuticals-gets-nmpa-green-light-for-apl-1202-clinical-trial-in-fla-infections/2024-10-12T10:12:53+08:00https://flcube.com/israeli-hair-transplant-innovator-hairstetics-launches-first-procedure-in-asia-at-hainan-hospital/2024-10-12T10:03:43+08:00https://flcube.com/hutchmed-halts-china-filing-for-gastric-cancer-drug-fruquintinib-following-regulatory-feedback/2024-10-11T14:27:36+08:00https://flcube.com/siemens-healthineers-7t-mri-system-terra-x-receives-nmpa-marketing-approval/2024-10-10T10:17:16+08:00